Serametrix, Ludwig Institute to Develop Cancer Rx-Response Test | GenomeWeb

NEW YORK (GenomeWeb News) — Personalized medicine company Serametrix announced today a partnership with the Ludwig Institute for Cancer Research to develop serum-based diagnostics to predict and monitor treatment response in cancer patients.

As part of the agreement, LICR has licensed to Serametrix tumor antigen patents surrounding the use of the antigen NY-ESO-1 as a predictor of drug response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.